GRP78 induced by estrogen plays a role in the chemosensitivity of endometrial cancer

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 132-139

  Luvsandagva, Baigalimaa ^a   Nakamura, Kazuto ^a   Kitahara, Yoshikazu ^a   Aoki, Hiroshi ^a   Murata, Tomomi ^a   Ikeda, Sadatomo ^a   Minegishi, Takashi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Endometrial cancer; Estrogen; GRP78; Molecular chaperone

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CISPLATIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GLUCOSE REGULATED PROTEIN 78; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER TISSUE; CELL DEATH; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CISPLATIN; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; PACLITAXEL; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84862766912     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.025     Document Type: Article

References (41)

1. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001;26:504-10. (Pubitemid 32735452)
2. Klausner RD, Sitia R. Protein degradation in the endoplasmic reticulum. Cell 1990;62:611-4.
3. Gazit G, Lu J, Lee AS. De-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res Treat 1999;54:135-46. (Pubitemid 29295316)
4. Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, Schwartz AM, et al. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 2000;59:15-26. (Pubitemid 30153894)
5. Little E, Ramakrishnan M, Roy B, Gazit G, Lee AS. The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. Crit Rev Eukaryot Gene Expr 1994;4:1-18. (Pubitemid 24238439)
6. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006;6:45-54.
7. Koumenis C. ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 2006;6:55-69.
8. Fu Y, Lee AS. Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 2006;5:741-4. (Pubitemid 44775126)
9. Jamora C, Dennert G, Lee AS. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci U S A 1996;93:7690-4. (Pubitemid 26277098)
10. Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, et al. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis 2006;23:401-10. (Pubitemid 46197122)
11. Boyle P, Leon ME, Maisonneuve P, Autier P. Cancer control in women. Update 2003. Int J Gynaecol Obstet 2003;83(Suppl. 1):179-202. (Pubitemid 39658501)
12. Cancer Facts and Figures. Atlanta: American Cancer Society; 2008. 2006.
13. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
14. Wataba K, Saito T, Fukunaka K, Ashihara K, Nishimura M, Kudo R. Over-expression of heat shock proteins in carcinogenic endometrium. Int J Cancer 2001;91:448-56. (Pubitemid 32115097)
15. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006;101:158-67.
16. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409-20. (Pubitemid 46359618)
17. Un F. G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers. Anticancer Drugs 2007;18:411-7. (Pubitemid 46712404)
18. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561-5. (Pubitemid 10073801)
19. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44. (Pubitemid 46630491)
20. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996;62:278-81. (Pubitemid 26274811)
21. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:3902-8. (Pubitemid 41079871)
22. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66. (Pubitemid 41095150)
23. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7. (Pubitemid 13194678)
24. Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987;10:237-46.
25. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000;13:379-88.
26. Nyholm HC, Nielsen AL, Lyndrup J, Norup P, Thorpe SM. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features. Am J Obstet Gynecol 1992;167:1334-42.
27. Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakir C, Sensu S, et al. The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol 2010;5(1):13.
28. Kauppila A. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol 1989;28:561-6. (Pubitemid 19238881)
29. Resendez Jr E, Wooden SK, Lee AS. Identification of highly conserved regulatory domains and protein-binding sites in the promoters of the rat and human genes encoding the stress-inducible 78-kilodalton glucose-regulated protein. Mol Cell Biol 1988;8:4579-84.
30. Kakiuchi C, Ishiwata M, Nanko S, Kunugi H, Minabe Y, Nakamura K, et al. Functional polymorphisms of HSPA5: possible association with bipolar disorder. Biochem Biophys Res Commun 2005;336:1136-43. (Pubitemid 41383440)
31. Petz LN, Nardulli AM. Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 2000;14:972-85. (Pubitemid 32250515)
32. Anderson I, Gorski J. Estrogen receptor alpha interaction with estrogen response element half-sites from the rat prolactin gene. Biochemistry 2000;39:3842-7. (Pubitemid 30183867)
33. Fu Y, Li J, Lee AS. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res 2007;67:3734-40. (Pubitemid 46762159)
34. Bifulco G, Miele C, Di Jeso B, Beguinot F, Nappi C, Di Carlo C, et al. Endoplasmic reticulum stress is activated in endometrial denocarcinoma. Gynecol Oncol Apr. 2012;125(1):220-5.
35. Bidus MA, Risinger JI, Chandramouli GV, Dainty LA, Litzi TJ, Berchuck A, et al. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clin Cancer Res 2006;12:83-8. (Pubitemid 43166180)
36. Chen Y, Yao Y, Zhang L, Li X, Wang Y, Zhao L, et al. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer. Exp Mol Pathol Aug. 2011;91(1):373-84.
37. Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001;19:4048-53. (Pubitemid 32976691)
38. Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 2005;192:1365-7.
39. Michener CM, Peterson G, Kulp B, Webster KD, Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol 2005;131:581-4. (Pubitemid 41558550)
40. Thigpen JT, Blessing JA, Homesley H, CreasmanWT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 1989;33:68-70. (Pubitemid 19106626)
41. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 2003;278:20915-24. (Pubitemid 36806399)